KR20190082229A - 스타필로코커스 감염에 대한 백신 구성체 및 이의 용도 - Google Patents

스타필로코커스 감염에 대한 백신 구성체 및 이의 용도 Download PDF

Info

Publication number
KR20190082229A
KR20190082229A KR1020197014191A KR20197014191A KR20190082229A KR 20190082229 A KR20190082229 A KR 20190082229A KR 1020197014191 A KR1020197014191 A KR 1020197014191A KR 20197014191 A KR20197014191 A KR 20197014191A KR 20190082229 A KR20190082229 A KR 20190082229A
Authority
KR
South Korea
Prior art keywords
polypeptide
lys
seq
ile
asn
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
KR1020197014191A
Other languages
English (en)
Korean (ko)
Inventor
프랑수아 말루앵
셀린 스떼르
줄리 코떼-그레이블
에릭 브뤼예뜨
Original Assignee
소크프라 시앙스 에 제니 에스.에.쎄.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 소크프라 시앙스 에 제니 에스.에.쎄. filed Critical 소크프라 시앙스 에 제니 에스.에.쎄.
Publication of KR20190082229A publication Critical patent/KR20190082229A/ko
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020197014191A 2016-10-21 2017-10-20 스타필로코커스 감염에 대한 백신 구성체 및 이의 용도 Abandoned KR20190082229A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662411120P 2016-10-21 2016-10-21
US62/411,120 2016-10-21
PCT/CA2017/051253 WO2018072031A1 (en) 2016-10-21 2017-10-20 Vaccine constructs and uses thereof against staphylococcus infections

Publications (1)

Publication Number Publication Date
KR20190082229A true KR20190082229A (ko) 2019-07-09

Family

ID=62018642

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197014191A Abandoned KR20190082229A (ko) 2016-10-21 2017-10-20 스타필로코커스 감염에 대한 백신 구성체 및 이의 용도

Country Status (24)

Country Link
US (2) US11324815B2 (https=)
EP (1) EP3529260A4 (https=)
JP (2) JP7181208B2 (https=)
KR (1) KR20190082229A (https=)
CN (1) CN109843910A (https=)
AR (1) AR109847A1 (https=)
AU (2) AU2017346974B2 (https=)
BR (1) BR112019007796A2 (https=)
CA (1) CA3037070A1 (https=)
CL (1) CL2019001048A1 (https=)
CO (1) CO2019005169A2 (https=)
CR (1) CR20190249A (https=)
DO (1) DOP2019000102A (https=)
IL (1) IL265869A (https=)
MX (2) MX2019004539A (https=)
MY (1) MY195369A (https=)
NZ (1) NZ751880A (https=)
PE (1) PE20191320A1 (https=)
PH (1) PH12019500843A1 (https=)
RU (2) RU2766354C2 (https=)
SG (2) SG10201912431XA (https=)
TW (1) TW201819402A (https=)
UY (1) UY37448A (https=)
WO (1) WO2018072031A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113777317A (zh) * 2020-06-09 2021-12-10 首都医科大学附属北京世纪坛医院 尿液主穹隆蛋白及其多肽片段在烧伤中的应用
WO2022125928A1 (en) * 2020-12-11 2022-06-16 Bayer Animal Health Gmbh Methods and compositions for improved production of an antigen for use in an s. aureus vaccine
WO2026014994A1 (ko) * 2024-07-12 2026-01-15 주식회사 더윤헬스텍 젖소 유방염 유래 대장균 또는 황색 포도알균 변이주 및 이를 포함하는 백신 조성물
US12161970B1 (en) 2024-08-09 2024-12-10 Jiaxing Research Institute, Zhejiang University CO2 desorption system suitable for limited space in complex sailing region and flexible control method

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE50983T1 (de) 1985-01-07 1990-03-15 Syntex Inc Oberflaechenaktive n-(omega, omega-1-dialkoxy)und n-(omega, omega-1-dialkenoxy)-alk-1-yl-n,n,ntrisubstituierte ammoniumverbindungen, deren herstellung und sie enthaltende pharmazeutische formulierungen.
US6228844B1 (en) 1991-11-12 2001-05-08 Vical Incorporated Stimulating vascular growth by administration of DNA sequences encoding VEGF
US7060458B1 (en) 1997-08-14 2006-06-13 Wyeth Nucleic acid and amino acid sequences relating to Staphylococcus epidermidis for diagnostics and therapeutics
US6380370B1 (en) 1997-08-14 2002-04-30 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Staphylococcus epidermidis for diagnostics and therapeutics
US6833134B2 (en) 2000-06-12 2004-12-21 University Of Saskacthewan Immunization of dairy cattle with GapC protein against Streptococcus infection
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
PL229487B1 (pl) 2002-11-12 2018-07-31 Brigham & Womens Hospital Inc Kompozycja zawierająca polimer β-1,6-glukozaminy, kompozycja zawierająca przeciwciało, kompozycja farmaceutyczna, sposób wytwarzania wyodrębnionego polisacharydu, sposób identyfikacji obecności deacetylowanej poli-N-acetyloglukozaminy (dPNAG) i/ lub poli-N-acetyloglukozaminy (PNAG), wyodrębniony polisacharyd do zastosowania w leczeniu lub profilaktyce zakażenia, wyodrębniony polisacharyd do zastosowania do wytwarzania przeciwciał, w tym przeciwciał monoklonalnych, wyodrębniony polisacharyd do zastosowania w identyfikacji przeciwciała monoklonalnego
CN1569893A (zh) 2003-07-21 2005-01-26 中国人民解放军军事医学科学院基础医学研究所 金葡菌毒力因子调控蛋白的抗原表位及其模拟表位和用途
RU2419628C2 (ru) 2004-09-22 2011-05-27 ГлаксоСмитКлайн Байолоджикалз с.а. Иммуногенная композиция для применения в вакцинации против стафилококков
EP2298341A3 (en) * 2004-10-21 2011-07-13 Wyeth LLC Immunogenic compositions of staphylococcus epidermidis polypeptide and polynucleotide antigens
WO2006059846A1 (en) 2004-12-01 2006-06-08 Lg Life Sciences, Ltd. Formulation of sec1 mutated protein and method for formulation of the same
CA2667788A1 (en) 2006-10-30 2008-12-18 The University Of Western Ontario Staphylococcus aureus specific anti-infectives
BRPI1011856A2 (pt) 2009-03-23 2020-11-03 Epitopix, Llc polipeptídeos e composições de imunização contendo polipeptídeos gram-positivos e métodos de uso
EP3263128A3 (en) 2009-04-14 2018-01-24 GlaxoSmithKline Biologicals S.A. Compositions for immunising against staphylococcus aureus
LT2547361T (lt) 2010-03-17 2020-12-28 Socpra - Sciences Et Génie, S.E.C. Staphylococcus aureus bakterinės vakcinos komponentai ir jų naudojimas
NZ764564A (en) 2011-06-19 2022-10-28 Univ New York Methods of treating and preventing staphylococcus aureus infections and associated conditions

Also Published As

Publication number Publication date
EP3529260A1 (en) 2019-08-28
RU2019115303A (ru) 2020-11-23
RU2766354C2 (ru) 2022-03-15
US20190216913A1 (en) 2019-07-18
WO2018072031A1 (en) 2018-04-26
CL2019001048A1 (es) 2019-08-30
RU2022100889A (ru) 2022-04-06
EP3529260A4 (en) 2020-12-16
BR112019007796A2 (pt) 2019-09-03
MY195369A (en) 2023-01-16
SG10201912431XA (en) 2020-02-27
JP2019531100A (ja) 2019-10-31
NZ751880A (en) 2023-04-28
AR109847A1 (es) 2019-01-30
CA3037070A1 (en) 2018-04-26
IL265869A (en) 2019-06-30
MX2019004539A (es) 2019-06-12
AU2022204585A1 (en) 2022-07-21
TW201819402A (zh) 2018-06-01
AU2017346974B2 (en) 2022-03-31
UY37448A (es) 2018-03-23
JP2023025066A (ja) 2023-02-21
DOP2019000102A (es) 2019-07-15
PH12019500843A1 (en) 2019-12-02
JP7181208B2 (ja) 2022-11-30
US20220288183A1 (en) 2022-09-15
PE20191320A1 (es) 2019-09-24
US11324815B2 (en) 2022-05-10
MX2023001219A (es) 2023-03-03
CO2019005169A2 (es) 2019-08-09
CN109843910A (zh) 2019-06-04
SG11201901483QA (en) 2019-03-28
RU2019115303A3 (https=) 2021-03-02
AU2017346974A1 (en) 2019-03-14
CR20190249A (es) 2019-10-16

Similar Documents

Publication Publication Date Title
RU2735101C2 (ru) Вакцинная композиция против инфекции, вызванной streptococcus suis
EP3167899B1 (en) Isolated polypeptide of the toxin a and toxin b proteins of c.difficile and uses thereof
JP2017193574A (ja) Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ ａｕｒｅｕｓに対して免疫化するための組成物
ES2834652T3 (es) Componentes de vacuna bacterianos de Staphylococcus aureus y usos de los mismos
JP2023025066A (ja) ワクチン構築物およびブドウ球菌感染症に対するその使用
AU2015246654B2 (en) Group A streptococcus vaccine
US20210393763A1 (en) Novel pneumococcal vaccine formulations
CN111787943B (zh) 作为疫苗的来自产气荚膜梭菌的ε毒素
JP2009509496A (ja) ローソニアイントラセルラリスの免疫学的タンパク
EP2424882A2 (en) Peptides protective against e. faecalis, methods and uses relating thereto
CN115151559A (zh) 葡萄球菌肽和使用方法
Bian et al. Preparation and evaluation of genetically engineered recombinant subunit vaccines containing serine metalloprotease, anchor M domain-containing protein, and pyolysin against Trueperella pyogenes infection in a mouse model
KR101680052B1 (ko) 탄저병의 예방 또는 치료를 위한 약제학적 조성물
HK40007546A (en) Vaccine constructs and uses thereof against staphylococcus infections
WO2022147238A1 (en) Burkholderia vaccines and therapeutics

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PC1904 Unpaid initial registration fee

St.27 status event code: A-2-2-U10-U14-oth-PC1904

St.27 status event code: N-2-6-B10-B12-nap-PC1904